Shree Pacetronix Ltd
₹ 79.8
-2.56%
06 Jun
3:01 p.m.
About
Incorporated in 1988, Shree Pacetronix Ltd manufactures and exports Implantable Cardiac Pacemakers.
Key Points
- Market Cap ₹ 28.7 Cr.
- Current Price ₹ 79.8
- High / Low ₹ 245 / 61.1
- Stock P/E 38.3
- Book Value ₹ 38.6
- Dividend Yield 0.00 %
- ROCE 8.92 %
- ROE 5.54 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding is low: 24.2%
- Debtor days have increased from 117 to 145 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.11 | 6.49 | 7.40 | 6.84 | 6.60 | 7.27 | 8.76 | 7.56 | 9.03 | 20.19 | 22.04 | 16.80 | |
| 5.82 | 5.34 | 6.22 | 6.34 | 5.80 | 6.52 | 7.52 | 6.45 | 7.44 | 14.75 | 16.28 | 14.60 | |
| Operating Profit | 1.29 | 1.15 | 1.18 | 0.50 | 0.80 | 0.75 | 1.24 | 1.11 | 1.59 | 5.44 | 5.76 | 2.20 |
| OPM % | 18.14% | 17.72% | 15.95% | 7.31% | 12.12% | 10.32% | 14.16% | 14.68% | 17.61% | 26.94% | 26.13% | 13.10% |
| 0.01 | -0.15 | -0.08 | 0.05 | 0.01 | 0.17 | 0.04 | 0.05 | 0.07 | 0.09 | 0.13 | 0.12 | |
| Interest | 0.46 | 0.41 | 0.35 | 0.38 | 0.31 | 0.30 | 0.36 | 0.34 | 0.28 | 0.30 | 0.45 | 0.58 |
| Depreciation | 0.51 | 0.68 | 0.69 | 0.57 | 0.39 | 0.38 | 0.51 | 0.51 | 0.50 | 0.63 | 0.82 | 0.70 |
| Profit before tax | 0.33 | -0.09 | 0.06 | -0.40 | 0.11 | 0.24 | 0.41 | 0.31 | 0.88 | 4.60 | 4.62 | 1.04 |
| Tax % | 33.33% | -66.67% | 116.67% | -27.50% | 36.36% | 41.67% | 31.71% | 41.94% | 26.14% | 29.35% | 27.49% | 26.92% |
| 0.22 | -0.04 | -0.01 | -0.29 | 0.08 | 0.14 | 0.28 | 0.18 | 0.65 | 3.25 | 3.36 | 0.75 | |
| EPS in Rs | 0.61 | -0.11 | -0.03 | -0.81 | 0.22 | 0.39 | 0.78 | 0.50 | 1.81 | 9.03 | 9.33 | 2.08 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 14% |
| 3 Years: | 23% |
| TTM: | -24% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 31% |
| 5 Years: | 23% |
| 3 Years: | 6% |
| TTM: | -78% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 49% |
| 3 Years: | 57% |
| 1 Year: | -61% |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 18% |
| 3 Years: | 22% |
| Last Year: | 6% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 |
| Reserves | 1.88 | 1.81 | 1.80 | 1.51 | 1.70 | 1.84 | 2.11 | 2.30 | 2.95 | 6.20 | 9.56 | 10.31 |
| 2.08 | 2.69 | 1.89 | 2.64 | 2.30 | 2.94 | 2.64 | 2.73 | 2.88 | 2.16 | 4.27 | 4.98 | |
| 1.27 | 0.95 | 1.31 | 1.28 | 1.29 | 1.27 | 1.99 | 2.07 | 2.62 | 4.64 | 4.39 | 4.15 | |
| Total Liabilities | 8.83 | 9.05 | 8.60 | 9.03 | 8.89 | 9.65 | 10.34 | 10.70 | 12.05 | 16.60 | 21.82 | 23.04 |
| 3.10 | 2.89 | 2.40 | 1.94 | 1.84 | 2.36 | 2.43 | 2.65 | 2.51 | 3.07 | 3.60 | 3.34 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.77 | 0.00 | 0.00 | 0.11 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.80 | 0.80 | 0.80 | 0.80 | 0.80 | 0.80 | 0.80 | 0.80 | 0.80 | 0.80 | 0.80 | 0.80 |
| 4.93 | 5.36 | 5.40 | 5.52 | 6.25 | 6.49 | 7.00 | 7.25 | 8.74 | 12.73 | 17.42 | 18.90 | |
| Total Assets | 8.83 | 9.05 | 8.60 | 9.03 | 8.89 | 9.65 | 10.34 | 10.70 | 12.05 | 16.60 | 21.82 | 23.04 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.13 | 0.36 | 1.32 | 0.57 | 0.08 | 0.63 | 1.49 | 0.99 | 0.59 | 2.40 | -0.03 | 0.95 | |
| -0.44 | -0.49 | -0.21 | -0.89 | 0.45 | -0.75 | -0.56 | -0.58 | -1.10 | -1.41 | -1.67 | -0.93 | |
| -0.90 | 0.19 | -1.11 | 0.24 | -0.48 | 0.26 | -0.81 | -0.15 | -0.14 | -0.96 | 1.75 | 0.12 | |
| Net Cash Flow | -0.21 | 0.07 | 0.00 | -0.07 | 0.06 | 0.14 | 0.12 | 0.26 | -0.65 | 0.03 | 0.05 | 0.14 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 91.38 | 64.68 | 78.92 | 102.46 | 174.20 | 154.13 | 162.50 | 194.57 | 209.78 | 108.65 | 96.22 | 145.13 |
| Inventory Days | 484.22 | 746.59 | 359.32 | 373.73 | 301.93 | 270.24 | 217.26 | 272.02 | 194.20 | 157.41 | 285.83 | 463.17 |
| Days Payable | 40.35 | 33.18 | 32.67 | 27.63 | 48.31 | 33.93 | 53.23 | 47.19 | 17.55 | 32.22 | 12.45 | 57.32 |
| Cash Conversion Cycle | 535.25 | 778.09 | 405.57 | 448.55 | 427.83 | 390.45 | 326.53 | 419.40 | 386.43 | 233.84 | 369.59 | 550.98 |
| Working Capital Days | 180.19 | 227.77 | 182.01 | 193.71 | 240.57 | 221.91 | 167.50 | 205.19 | 202.10 | 119.14 | 182.33 | 260.28 |
| ROCE % | 10.28% | 3.83% | 5.33% | -0.40% | 5.47% | 5.13% | 9.09% | 7.54% | 12.51% | 45.82% | 34.50% | 8.92% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
31 May - Dear Sir/Madam, Kindly find enclosed herewith the extracts of Newspaper Publication Pursuant to Regulation 47 of SEBI (LODR) Regulations, 2015 of the Audited Standalone and …
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 30.05.2025
30 May - Approved FY25 audited results with modified opinion; appointed new auditors and company secretary.
-
Submission Of Audited Financial Results (Standalone And Consolidated) Along With Audit Report For The Quarter And Financial Year Ended 31St March 2025.
30 May - Audited FY25 results with qualified opinion due to suspended subsidiary project investment impairment risk.
-
Announcement under Regulation 30 (LODR)-Change in Management
30 May - Appointed secretarial auditor for 5 years, internal auditor for FY 2025-26; company secretary resigned and new appointed.
-
Board Meeting Intimation for Intimation Of Board Meeting (01St/2025-2026) Of The Company.
21 May - Board meeting on May 30 to approve FY25 audited financial results; trading window closed Apr 1-Jun 1.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Profile:[1][2]
Company deals in 3 major products viz, Pacemakers, Pacing Leads, Pacing System which are further bifurcated as: Ventralite 940+/ Tiranga, Pinnacle-8820, Tiranga -302, Pinnacle-R-SSIR-Model-29, Trinity-R, Smart - E, Atrial-J-Bipolar-Lead-3851-VB, Introducer, Zeus -1, Is1 Bipolar Lead 3851 Vb, Screw-in Lead P12, Pace Maker Analyser, Charak DDDR, Indus I SSB, Implantable Cardioverter Pacemaker, Single Chamber Pacemaker, Reuters Pacemakers, Permanent Pacemaker, Medtronic Pacemaker, Pacing System Analyzer